Canerpaturev clinical trials
Also written HF10.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses canerpaturev is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Takara Bio Inc. (4) · University of Utah (1)
Studies
Open first, then newest update. How each study uses canerpaturev is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic MelanomaCompletedPhase 2Takara Bio Inc.NCT03153085Written as TBI-1401(HF10)
- Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a MelanomaTerminatedPhase 2University of UtahNCT03259425Written as HF10
- Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial LesionsCompletedPhase 1Takara Bio Inc.NCT01017185Written as HF10
- A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic MelanomaCompletedPhase 2Takara Bio Inc.NCT02272855Written as HF10 plus Ipilimumab
- A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial LesionsCompletedPhase 1Takara Bio Inc.NCT02428036Written as TBI-1401(HF10)
Given beside what is tested · 1 — canerpaturev is usual care or a partner of the new treatment
Codes
What other systems call canerpaturev · ClinicalTrials.gg INT017447
- UNII (FDA) O3F5D10T4MCANERPATUREVOne source FDA
- NCI Thesaurus C88318CanerpaturevOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | O3F5D10T4M | CANERPATUREV | One source FDA |
| NCI Thesaurus | C88318 | Canerpaturev | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.